San Diego, CA — October 31, 2025 — Leads & Copy — Quantumzyme Corp. (OTCQB: QTZM) announced the World Intellectual Property Organization (WIPO) publication of its international patent application, “Modified Polypeptides for Enzymatic Synthesis of Ibuprofen” (Publication No. WO 2025/093935 A1).
The company is highlighting its ongoing progress and commitment to growth through innovation in sustainable pharmaceutical manufacturing. The announcement also reflects the company’s broader growth strategy, which centers on expanding its enzyme engineering capabilities, strengthening its intellectual property portfolio, and advancing discussions with potential global partners.
The company previously announced the publication of its U.S. Patent Application (U.S. Patent Application Publication No. US 2025/0146029 A1) covering related enzymatic processes. Together, these filings establish broad protection for Quantumzyme’s proprietary enzyme engineering platform in both the United States and international markets.
According to the company, these publications strengthen Quantumzyme’s international intellectual property portfolio and represent a major step toward commercializing its enzymatic process for the sustainable manufacture of ibuprofen. These patents cover the company’s proprietary biocatalytic method for producing ibuprofen through an enzyme-mediated process designed to reduce chemical waste, eliminate harsh reagents, and enhance overall manufacturing efficiency.
Naveen Kulkarni, CEO of Quantumzyme Corp., stated the publication of their patents mark an important milestone for Quantumzyme, validating the strength of their enzyme engineering technology and enhances the position for global partnerships focused on greener, more efficient pharmaceutical manufacturing. It also allows them to advance into the optimization and pilot-testing phase and engage with potential partners interested in sustainable and scalable API production.
The patented ibuprofen synthesis builds on Quantumzyme’s proprietary QZyme Workbench™ platform, which integrates quantum mechanics, molecular modeling, and AI-driven optimization to design next-generation biocatalysts.
Quantumzyme intends to continue laboratory optimization and scale-up validation of the enzymatic ibuprofen synthesis process; pursue discussions with global pharmaceutical and contract manufacturing organizations (CMOs) regarding licensing or joint-development frameworks; and file additional patent applications covering related enzymatic transformations and process improvements.
Contact:
Naveen Kulkarni
Chief Executive Officer
Quantumzyme Corp.
15656 Bernardo Center Drive, Suite 801
San Diego, CA 92127
Phone: +1 (858) 203-0312
Email: info@quantumzymecorp.com
